Interpace Biosciences Inc
OTC:IDXG
Interpace Biosciences Inc
OTC:IDXG
Price:
1.55 USD
4.73%
Market Closed
Updated:
May 29, 2024
Interpace Biosciences Inc
Other Current Liabilities
|
Interpace Biosciences Inc
Other Current Liabilities Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Interpace Biosciences Inc
OTC:IDXG
|
Other Current Liabilities
$1.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-18%
|
|
|
DaVita Inc
NYSE:DVA
|
Other Current Liabilities
$942.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-3%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CVS Health Corp
NYSE:CVS
|
Other Current Liabilities
$2.4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Other Current Liabilities
$33.3B
|
CAGR 3-Years
34%
|
CAGR 5-Years
24%
|
CAGR 10-Years
32%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Other Current Liabilities
$377.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
47%
|
See Also
What is Interpace Biosciences Inc's Other Current Liabilities?
Other Current Liabilities
1.2m
USD
1.2m
USD
Based on the financial report for Mar 31, 2024, Interpace Biosciences Inc's Other Current Liabilities amounts to 1.2m USD.
What is Interpace Biosciences Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-18%
-18%
Over the last year, the Other Current Liabilities growth was -44%. The average annual Other Current Liabilities growth rates for Interpace Biosciences Inc have been -19% over the past three years , -12% over the past five years , and -18% over the past ten years .
You don't have any saved screeners yet
